Then, stattic experiments have demonstrated that Y705-STAT3 positively regulated the expression of mediators that can facilitate the ability of HR+/HER2− cells to use the TME for their own benefit: potentiating the inflammatory nature of the TME by increasing the levels of CXCL8, and down-regulating anti-tumor acquired immune activities by the elevated expression of PD-L1 by the tumor cells. Here, STAT3 is linked to neoplasm.